Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility? - Archive ouverte HAL Access content directly
Journal Articles Targeted Oncology Year : 2012

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

(1) , (1) , (1)
1

Abstract

The adoptive transfer of tumor antigen-specific T cells recently achieved clinical efficacy for a fraction of melanoma patients refractory to other therapies. Unfortunately , the application of this strategy to the remaining melanoma and most other cancer patients is hampered by the difficulty to generate high-affinity tumor-reactive T cells. Two strategies are currently developed to extend the feasibility of this therapeutic approach: clinical grade tool production for MHC-peptide multimer-driven sorting of antigen-specific T cells from the endogenous peripheral T cell repertoire and de novo engineering of the missing repertoire by genetic transfer of cloned specific T cell receptor (TCR) into T cells. The expected multiplication of adoptive transfer treatments, by these strategies, and their careful evaluation should enable the cure of a number of otherwise compromised cancer patients and to gain insight into the characteristics of transferred T cells best fitted to eradicate tumor cells, in terms of antigen specificities, phenotype, and functions. In particular, identification of tumor-rejection antigens by this approach would improve the design and efficacy of all immuno-therapeutic approaches.
Fichier principal
Vignette du fichier
Jotereau2012.pdf (467.13 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-02483714 , version 1 (18-02-2020)

Identifiers

Cite

Francine Jotereau, Nadine Gervois, Nathalie Labarrière. Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?. Targeted Oncology, 2012, 7 (1), pp.3-14. ⟨10.1007/s11523-012-0207-z⟩. ⟨inserm-02483714⟩
23 View
91 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More